B-cell lymphoma 2 Inhibitors Market, Global Outlook and Forecast 2022-2028

March 2022 | 63 pages | ID: B43F39300E6CEN
Market Monitor Global

Abstracts

Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis.

This report contains market size and forecasts of B-cell lymphoma 2 Inhibitors in Global, including the following market information:

Global B-cell lymphoma 2 Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global B-cell lymphoma 2 Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Combination Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of B-cell lymphoma 2 Inhibitors include AbbVie Inc., F. Hoffmann-La Roche Ltd., Santa Cruz Biotechnology, Tocris and Biovision, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the B-cell lymphoma 2 Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global B-cell lymphoma 2 Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global B-cell lymphoma 2 Inhibitors Market Segment Percentages, by Type, 2021 (%)

• Combination Therapy
• Monotherapy

Global B-cell lymphoma 2 Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global B-cell lymphoma 2 Inhibitors Market Segment Percentages, by Application, 2021 (%)

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Cute Myeloid Leukemia

Global B-cell lymphoma 2 Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global B-cell lymphoma 2 Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies B-cell lymphoma 2 Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies B-cell lymphoma 2 Inhibitors revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Santa Cruz Biotechnology
• Tocris
• Biovision

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 B-cell lymphoma 2 Inhibitors Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global B-cell lymphoma 2 Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL B-CELL LYMPHOMA 2 INHIBITORS OVERALL MARKET SIZE

2.1 Global B-cell lymphoma 2 Inhibitors Market Size: 2021 VS 2028
2.2 Global B-cell lymphoma 2 Inhibitors Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top B-cell lymphoma 2 Inhibitors Players in Global Market
3.2 Top Global B-cell lymphoma 2 Inhibitors Companies Ranked by Revenue
3.3 Global B-cell lymphoma 2 Inhibitors Revenue by Companies
3.4 Top 3 and Top 5 B-cell lymphoma 2 Inhibitors Companies in Global Market, by Revenue in 2021
3.5 Global Companies B-cell lymphoma 2 Inhibitors Product Type
3.6 Tier 1, Tier 2 and Tier 3 B-cell lymphoma 2 Inhibitors Players in Global Market
  3.6.1 List of Global Tier 1 B-cell lymphoma 2 Inhibitors Companies
  3.6.2 List of Global Tier 2 and Tier 3 B-cell lymphoma 2 Inhibitors Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global B-cell lymphoma 2 Inhibitors Market Size Markets, 2021 & 2028
  4.1.2 Combination Therapy
  4.1.3 Monotherapy
4.2 By Type - Global B-cell lymphoma 2 Inhibitors Revenue & Forecasts
  4.2.1 By Type - Global B-cell lymphoma 2 Inhibitors Revenue, 2017-2022
  4.2.2 By Type - Global B-cell lymphoma 2 Inhibitors Revenue, 2023-2028
  4.2.3 By Type - Global B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global B-cell lymphoma 2 Inhibitors Market Size, 2021 & 2028
  5.1.2 Chronic Lymphocytic Leukemia
  5.1.3 Small Lymphocytic Lymphoma
  5.1.4 Cute Myeloid Leukemia
5.2 By Application - Global B-cell lymphoma 2 Inhibitors Revenue & Forecasts
  5.2.1 By Application - Global B-cell lymphoma 2 Inhibitors Revenue, 2017-2022
  5.2.2 By Application - Global B-cell lymphoma 2 Inhibitors Revenue, 2023-2028
  5.2.3 By Application - Global B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global B-cell lymphoma 2 Inhibitors Market Size, 2021 & 2028
6.2 By Region - Global B-cell lymphoma 2 Inhibitors Revenue & Forecasts
  6.2.1 By Region - Global B-cell lymphoma 2 Inhibitors Revenue, 2017-2022
  6.2.2 By Region - Global B-cell lymphoma 2 Inhibitors Revenue, 2023-2028
  6.2.3 By Region - Global B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America B-cell lymphoma 2 Inhibitors Revenue, 2017-2028
  6.3.2 US B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.3.3 Canada B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.3.4 Mexico B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe B-cell lymphoma 2 Inhibitors Revenue, 2017-2028
  6.4.2 Germany B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.4.3 France B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.4.4 U.K. B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.4.5 Italy B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.4.6 Russia B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.4.7 Nordic Countries B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.4.8 Benelux B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia B-cell lymphoma 2 Inhibitors Revenue, 2017-2028
  6.5.2 China B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.5.3 Japan B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.5.4 South Korea B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.5.5 Southeast Asia B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.5.6 India B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America B-cell lymphoma 2 Inhibitors Revenue, 2017-2028
  6.6.2 Brazil B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.6.3 Argentina B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa B-cell lymphoma 2 Inhibitors Revenue, 2017-2028
  6.7.2 Turkey B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.7.3 Israel B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.7.4 Saudi Arabia B-cell lymphoma 2 Inhibitors Market Size, 2017-2028
  6.7.5 UAE B-cell lymphoma 2 Inhibitors Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie Inc.
  7.1.1 AbbVie Inc. Corporate Summary
  7.1.2 AbbVie Inc. Business Overview
  7.1.3 AbbVie Inc. B-cell lymphoma 2 Inhibitors Major Product Offerings
  7.1.4 AbbVie Inc. B-cell lymphoma 2 Inhibitors Revenue in Global Market (2017-2022)
  7.1.5 AbbVie Inc. Key News
7.2 F. Hoffmann-La Roche Ltd.
  7.2.1 F. Hoffmann-La Roche Ltd. Corporate Summary
  7.2.2 F. Hoffmann-La Roche Ltd. Business Overview
  7.2.3 F. Hoffmann-La Roche Ltd. B-cell lymphoma 2 Inhibitors Major Product Offerings
  7.2.4 F. Hoffmann-La Roche Ltd. B-cell lymphoma 2 Inhibitors Revenue in Global Market (2017-2022)
  7.2.5 F. Hoffmann-La Roche Ltd. Key News
7.3 Santa Cruz Biotechnology
  7.3.1 Santa Cruz Biotechnology Corporate Summary
  7.3.2 Santa Cruz Biotechnology Business Overview
  7.3.3 Santa Cruz Biotechnology B-cell lymphoma 2 Inhibitors Major Product Offerings
  7.3.4 Santa Cruz Biotechnology B-cell lymphoma 2 Inhibitors Revenue in Global Market (2017-2022)
  7.3.5 Santa Cruz Biotechnology Key News
7.4 Tocris
  7.4.1 Tocris Corporate Summary
  7.4.2 Tocris Business Overview
  7.4.3 Tocris B-cell lymphoma 2 Inhibitors Major Product Offerings
  7.4.4 Tocris B-cell lymphoma 2 Inhibitors Revenue in Global Market (2017-2022)
  7.4.5 Tocris Key News
7.5 Biovision
  7.5.1 Biovision Corporate Summary
  7.5.2 Biovision Business Overview
  7.5.3 Biovision B-cell lymphoma 2 Inhibitors Major Product Offerings
  7.5.4 Biovision B-cell lymphoma 2 Inhibitors Revenue in Global Market (2017-2022)
  7.5.5 Biovision Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. B-cell lymphoma 2 Inhibitors Market Opportunities & Trends in Global Market
Table 2. B-cell lymphoma 2 Inhibitors Market Drivers in Global Market
Table 3. B-cell lymphoma 2 Inhibitors Market Restraints in Global Market
Table 4. Key Players of B-cell lymphoma 2 Inhibitors in Global Market
Table 5. Top B-cell lymphoma 2 Inhibitors Players in Global Market, Ranking by Revenue (2021)
Table 6. Global B-cell lymphoma 2 Inhibitors Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global B-cell lymphoma 2 Inhibitors Revenue Share by Companies, 2017-2022
Table 8. Global Companies B-cell lymphoma 2 Inhibitors Product Type
Table 9. List of Global Tier 1 B-cell lymphoma 2 Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 B-cell lymphoma 2 Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - B-cell lymphoma 2 Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - B-cell lymphoma 2 Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - B-cell lymphoma 2 Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - B-cell lymphoma 2 Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Inc. Corporate Summary
Table 31. AbbVie Inc. B-cell lymphoma 2 Inhibitors Product Offerings
Table 32. AbbVie Inc. B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), (2017-2022)
Table 33. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 34. F. Hoffmann-La Roche Ltd. B-cell lymphoma 2 Inhibitors Product Offerings
Table 35. F. Hoffmann-La Roche Ltd. B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), (2017-2022)
Table 36. Santa Cruz Biotechnology Corporate Summary
Table 37. Santa Cruz Biotechnology B-cell lymphoma 2 Inhibitors Product Offerings
Table 38. Santa Cruz Biotechnology B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), (2017-2022)
Table 39. Tocris Corporate Summary
Table 40. Tocris B-cell lymphoma 2 Inhibitors Product Offerings
Table 41. Tocris B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), (2017-2022)
Table 42. Biovision Corporate Summary
Table 43. Biovision B-cell lymphoma 2 Inhibitors Product Offerings
Table 44. Biovision B-cell lymphoma 2 Inhibitors Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. B-cell lymphoma 2 Inhibitors Segment by Type in 2021
Figure 2. B-cell lymphoma 2 Inhibitors Segment by Application in 2021
Figure 3. Global B-cell lymphoma 2 Inhibitors Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global B-cell lymphoma 2 Inhibitors Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global B-cell lymphoma 2 Inhibitors Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by B-cell lymphoma 2 Inhibitors Revenue in 2021
Figure 8. By Type - Global B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 9. By Application - Global B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 10. By Region - Global B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 11. By Country - North America B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 12. US B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 13. Canada B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 16. Germany B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 17. France B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 19. Italy B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 20. Russia B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 24. China B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 25. Japan B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 28. India B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 30. Brazil B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa B-cell lymphoma 2 Inhibitors Revenue Market Share, 2017-2028
Figure 33. Turkey B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 34. Israel B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 36. UAE B-cell lymphoma 2 Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Inc. B-cell lymphoma 2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. F. Hoffmann-La Roche Ltd. B-cell lymphoma 2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Santa Cruz Biotechnology B-cell lymphoma 2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Tocris B-cell lymphoma 2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Biovision B-cell lymphoma 2 Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)